SLAC and Stanford researchers have secured funding for two projects that share one goal: to reduce the side effects of radiation therapy by vastly shrinking the length of a typical session.
New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second.
Researchers at SLAC and Stanford received funding to develop two possible treatments for tumors one using X-rays, the other using protons. The idea behind both is to blast cancer cells so quickly that organs and other tissues don’t have time to move during the exposure, much like taking a single freeze frame from a video. This reduces the chance that radiation will hit and damage healthy tissue around tumors, making radiation therapy more precise.
“Delivering the radiation dose of an entire therapy session with a single flash lasting less than a second would be the ultimate way of managing the constant motion of organs and tissues, and a major advance compared with methods we’re using today,” said Billy Loo, MD, PhD, an associate professor of radiation oncology.
Sami Tantawi, PhD, a professor of particle physics and astrophysics and the chief scientist for the RF Accelerator Research Division in SLAC’s Technology Innovation Directorate, works with Loo on both projects.
“In order to deliver high-intensity radiation efficiently enough, we need accelerator structures that are hundreds of times more powerful than today’s technology,” Tantawi said. “The funding we received will help us build these structures.”
Blasting cancer with X-rays
A project called PHASER will develop a flash delivery system for X-rays. In today’s medical devices, electrons fly through a tube-like accelerator structure that’s about a meter long, gaining energy from a radiofrequency field that travels through the tube at the same time and in the same direction. The energy of the electrons then gets converted into X-rays.
Over the past few years, the PHASER team has developed and tested accelerator prototypes with special shapes and new ways of feeding radiofrequency fields into the tube. These components are already performing as predicted by simulations and could pave the way for accelerator designs that support more power in a compact size.
“Next, we will build the accelerator structure and test the risks of the technology, which, in three to five years, could lead to a first actual device that can eventually be used in clinical trials,” Tantawi said.
The Department of Radiation Oncology will provide about $1 million over the next year for these efforts and support a campaign to raise more research funding. In collaboration with the School of Medicine, the department also has established the Radiation Science Center, which focuses on precision radiation treatment. Its PHASER division, co-led by Loo and Tantawi, aims to turn the PHASER concept into a functional device.
Making proton therapy more agile
In principle, protons are less harmful to healthy tissue than X-rays because they deposit their tumor-killing energy in a more confined volume inside the body. However, proton therapy requires large facilities to accelerate protons and adjust their energy. It also uses magnets weighing hundreds of tons that slowly move around a patient’s body to guide the beam to the target.
“We want to come up with innovative ways to manipulate the proton beam that will make future devices simpler, more compact and much faster,” said Emilio Nanni, PhD, a staff scientist at SLAC who leads this project with Tantawi and Loo.
That goal could soon be within reach, thanks to a recent $1.7 million grant from the DOE Office of Science Accelerator Stewardship program to develop the technology over the next three years.
“We can now move forward with designing, fabricating and testing an accelerator structure similar to the one in the PHASER project that will be capable of steering the proton beam, tuning its energy and delivering high radiation doses practically instantaneously,” Nanni said.